Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Kip P. Conner"'
Autor:
Shufang Liu, Sara C. Humphreys, Kevin D. Cook, Kip P. Conner, Ana R. Correia, Alex W. Jacobitz, Melissa Yang, Ronya Primack, Marcus Soto, Rupa Padaki, Mariusz Lubomirski, Richard Smith, Marissa Mock, Veena A. Thomas
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTIn this investigation, we tested the hypothesis that a physiologically based pharmacokinetic (PBPK) model incorporating measured in vitro metrics of off-target binding can largely explain the inter-antibody variability in monoclonal antibody
Externí odkaz:
https://doaj.org/article/ba5447ad553b4a998a1ea0915308c3b4
Autor:
Marissa Mock, Alex W. Jacobitz, Christopher James Langmead, Athena Sudom, Daniel Yoo, Sara C. Humphreys, Mai Alday, Larysa Alekseychyk, Nicolas Angell, Vivian Bi, Hannah Catterall, Chen-Chun Chen, Hui-Ting Chou, Kip P. Conner, Kevin D. Cook, Ana R. Correia, Andrew Dykstra, Sudipa Ghimire-Rijal, Kevin Graham, Peter Grandsard, Joon Huh, John O. Hui, Mani Jain, Victoria Jann, Lei Jia, Sheree Johnstone, Neelam Khanal, Carl Kolvenbach, Linda Narhi, Rupa Padaki, Emma M. Pelegri-O’Day, Wei Qi, Vladimir Razinkov, Austin J. Rice, Richard Smith, Christopher Spahr, Jennitte Stevens, Yax Sun, Veena A. Thomas, Sarah van Driesche, Robert Vernon, Victoria Wagner, Kenneth W. Walker, Yangjie Wei, Dwight Winters, Melissa Yang, Iain D. G. Campuzano
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTBiologic drug discovery pipelines are designed to deliver protein therapeutics that have exquisite functional potency and selectivity while also manifesting biophysical characteristics suitable for manufacturing, storage, and convenient admin
Externí odkaz:
https://doaj.org/article/c7e86c82a6684b888888da7d561e8891
Autor:
Kip P. Conner, Cinthia V. Pastuskovas, Marcus Soto, Veena A. Thomas, Mylo Wagner, Dan A. Rock
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
The decision to pursue a monoclonal antibody (mAb) as a therapeutic for disease intervention requires the assessment of many factors, such as target-biology, including the total target burden and its accessibility at the intended site of action, as w
Externí odkaz:
https://doaj.org/article/243a6b7f7dbe4e909e8a123c532462bf
Autor:
Matthew F. Krummel, Kip P. Conner, Dan A. Rock, Hugo Gonzalez Velozo, Arja Ray, Jordan Artichoker, Ran You
Supplementary Data from Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03e2f14732c157287b0492aeffe06b7a
https://doi.org/10.1158/2326-6066.22544619.v1
https://doi.org/10.1158/2326-6066.22544619.v1
Autor:
Matthew F. Krummel, Kip P. Conner, Dan A. Rock, Hugo Gonzalez Velozo, Arja Ray, Jordan Artichoker, Ran You
Bispecific T-cell engager (BiTE) molecules are biologic T cell–directing immunotherapies. Blinatumomab is approved for treatment of B-cell malignancies, but BiTE molecule development in solid tumors has been more challenging. Here, we employed intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ec3a7abb85c02ebac53e9cf6e06738f
https://doi.org/10.1158/2326-6066.c.6550704
https://doi.org/10.1158/2326-6066.c.6550704
Autor:
Ran You, Jordan Artichoker, Arja Ray, Hugo Gonzalez Velozo, Dan A. Rock, Kip P. Conner, Matthew F. Krummel
Publikováno v:
Cancer immunology research, vol 10, iss 6
Cancer Immunol Res
Cancer Immunol Res
Bispecific T-cell engager (BiTE) molecules are biologic T cell–directing immunotherapies. Blinatumomab is approved for treatment of B-cell malignancies, but BiTE molecule development in solid tumors has been more challenging. Here, we employed intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b8421509364861b2f95f4f03d2027e
https://doi.org/10.1158/2326-6066.cir-21-0594
https://doi.org/10.1158/2326-6066.cir-21-0594
Autor:
Brad Herberich, Thomas Nixey, Lin Yin, Tayo Ikotun, Kelvin K. C. Sham, Jason Long, Hongyan Li, Charles Glaus, Xuhai Be, Les P. Miranda, Yuan Cheng, Marcus Soto, James R. Falsey, Bryan D. Moyer, Robert S. Foti, Christopher M. Tegley, Chawita Netirojjanakul, Linh Tran, Kip P. Conner, Jennifer Aral, Liyue Huang, Kaustav Biswas, Justin K. Murray, Bin Wu, Loren Berry, Dean Hickman, Dan A. Rock
Publikováno v:
Drug Metabolism and Disposition. 47:1111-1121
The identification of nonopioid alternatives to treat chronic pain has received a great deal of interest in recent years. Recently, the engineering of a series of Nav1.7 inhibitory peptide-antibody conjugates has been reported, and herein, the precli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aafa704103c2cd45fe6f198cffc5d5f
https://doi.org/10.1124/dmd.119.087742
https://doi.org/10.1124/dmd.119.087742
Autor:
Kip P. Conner, Min-Zu Wu, Jiamiao Lu, Aazam Ghelani, Yi-Ling Hu, Darren L. Bates, Ashutosh Chaudhry, Sue J. Sohn, Chi-Ming Li
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology, Vol 11 (2020)
Among all T and NK cell subsets, regulatory T (Treg) cells typically respond to the lowest concentrations of IL-2 due to elevated surface expression of the IL-2R alpha chain (IL2RA; CD25) and the high affinity IL-2 receptor (IL-2R) complex. This enha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c5300a7e9e52e6055f1cfa65656b9af
https://pubmed.ncbi.nlm.nih.gov/32582190
https://pubmed.ncbi.nlm.nih.gov/32582190
Autor:
Alex A. Cruce, Carson J. Mize, William M. Atkins, Michael K. Bowman, Molly M. Lockart, Joseph T. Butler, Kip P. Conner, Morgan N. Fair
Publikováno v:
J Inorg Biochem
The Mycobacterium tuberculosis (Mtb) genome encodes 20 different cytochrome P450 enzymes (CYPs), many of which serve essential biosynthetic roles. CYP51B1, the Mtb version of eukaryotic sterol demethylase, remains a potential therapeutic target. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62bdd1f04d57790efca2fe62d4e9977d
https://doi.org/10.1016/j.jinorgbio.2020.110994
https://doi.org/10.1016/j.jinorgbio.2020.110994
Autor:
Brooke M. Rock, Kip P. Conner, Jason W. O'Neill, Mark E. Tometsko, Tiep Le, Kevin J. Hamblett, Justin N. Huard, Robert R. Milburn, Dan A. Rock, Sophia Siu, William C. Fanslow
Publikováno v:
Molecular pharmaceutics. 13(7)
Antibody-drug conjugates (ADC) rely on the target-binding specificity of an antibody to selectively deliver potent drugs to cancer cells. IgG antibody half-life is regulated by neonatal Fc receptor (FcRn) binding. Histidine 435 of human IgG was mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdc19d98e0589e41f65bb7eea6be00ac
https://pubmed.ncbi.nlm.nih.gov/27248573
https://pubmed.ncbi.nlm.nih.gov/27248573